Novartis to Acquire MorphoSys for US$2.9 B to Expand Oncology Pipeline.
In: PharmaDeals Review, Jg. 2024 (2024-02-01), Heft 2, S. 6-6
serialPeriodical
Zugriff:
Novartis has agreed to acquire MorphoSys for €2.9 billion in order to expand its oncology pipeline. The acquisition will include MorphoSys' late-stage candidate for myelofibrosis and an early-stage investigational therapeutic for solid tumors or lymphomas. This move by Novartis is aimed at diversifying its therapeutic offerings and strengthening its pipeline in oncology. The acquisition has been unanimously approved by both companies' Board of Directors and is expected to close in the first half of 2024. [Extracted from the article]
Copyright of PharmaDeals Review is the property of IMS Health and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Novartis to Acquire MorphoSys for US$2.9 B to Expand Oncology Pipeline.
|
---|---|
Autor/in / Beteiligte Person: | Mishra, Lalit |
Zeitschrift: | PharmaDeals Review, Jg. 2024 (2024-02-01), Heft 2, S. 6-6 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1756-7874 (print) |
DOI: | 10.3833/pdr.v2024.i2.2853 |
Schlagwort: |
|
Sonstiges: |
|